Renowned stock market guru and CNBC host, Jim Cramer, weighed in on the potential value of GLP-1 drugs, commonly used to treat diabetes and obesity, as well as the companies producing them, such as Eli Lilly and Novo Nordisk. Cramer stated that these drugs could be extremely valuable with a significant impact on the pharmaceutical…
CNBC Investing Club with Jim Cramer: Key Moments from Monday’s Morning Meeting The CNBC Investing Club with Jim Cramer held its Morning Meeting livestream at 10:20 a.m. ET on Monday, discussing the latest developments in the stock market. Here are the key moments from the meeting: 1. U.S. equities experienced pressure on Monday, with the…
Eli Lilly’s stock saw a significant increase on Wednesday after the U.S. government approved the company’s GLP-1 drug for obesity treatment. The FDA’s decision was no surprise, and now Eli Lilly is gearing up to market the drug as Zepbound. The stock price soared by almost 2% in response to the news, reaching $611.36 per…
